Hormonal replacement therapy after gynaecological cancer

Gynakologisch-geburtshilfliche Rundschau

Volumn 46, Issue 4, 2006, Pages 191-196

  Biglia, Nicoletta ^a,b   Mariani, Luca ^a   Marenco, Davide ^a   Robba, Claudio ^a   Peano, Elisa ^a   Kubatzki, Franziska ^a   Sismondi, Piero ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

Gynaecological and breast cancer survivors; Hormone replacement therapy; Menopause

Indexed keywords

ESTROGEN;

BREAST CANCER; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INFORMATION; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; OVARY CANCER; POSTOPERATIVE PERIOD; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; UTERINE CERVIX CANCER;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HUMANS; LYMPHATIC METASTASIS; MENOPAUSE; MENOPAUSE, PREMATURE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; SURVIVORS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 33750462730     PISSN: 10188843     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095727     Document Type: Review

References (45)

1. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-330.
2. Lee R, Burke T, Park R: Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-191.
3. Chapman J, Di Saia P, Osann K, Roth P, Gillotte D, Berman M: Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-2000.
4. Suriano KA, Mchale M, Mclaren CE, Li KT, Re A, Di Saia PJ: Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555-560.
5. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS: Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587-592.
6. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Levgur M: Estrogen and combined hormone therapy for women after genital malignancies. J Reprod Med 2004;49:837-848.
8. Ayhan A, Taskiran C, Simsek S, Sever A: Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 2006;16:805-808.
9. Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F, Sismondi P: Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29-38.
10. North American Menopause Society: Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11-33.
11. Dew J, Eden J, Beller E: A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137-142.
12. Eden JA, Bush T, Nand S: A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause J North Am Menopause Soc 1995;2:67-72.
13. Powles TJ, Hickish T, Casey S: Hormone replacement after breast cancer. Lancet 1993;342:60-61.
14. Stoll BA: Hormone replacement therapy in women treated for breast cancer. Eur J Clin Oncol 1989;25:1909-1913.
15. Ursic-Vrscaj M, Bebar S: A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146-151.
16. Marsden J, Baum M, Withehead MI: A randomised trial of HRT in women with a history of breast cancer: a feasibility study (abstract). Acta Obstet Gynecol Scand 1997;76(suppl 167):22.
17. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN: Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482-1487.
18. Wile AG, Opfell RW, Margileth DA: Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-375.
19. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS: Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-762.
20. Gorins A, Espie M, Bedairia N, Perret F, Tournant B, Novak H, Lucchi-Angelier E, Marty M: Hormone replacement therapy in breast cancer patients: a study of 230 patients, with a case-control study. Gynecol Obstet Fertil 2003;31:614-619.
21. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J: Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357-2363.
22. Consensus Statement on Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998;83:1993-2000.
23. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL, Theriault RL: Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 2002;95:1817-1826.
24. Holmberg L, Anderson H: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-455.
25. Von Schoultz E, Rutqvist LE, on behalf of the Stockholm Breast Cancer Study Group: Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005;97:533-535.
26. Chlebowski RT, Anderson GL: Progestins and recurrence in breast cancer survivors (editorial). J Natl Cancer Inst 2005;97:471-472.
27. North American Menopause Society: Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11-33.
28. Jemal A, Murray T, Samuels A: Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
29. Yancik R, Ries LG, Yates JW: Ovarian cancer in the elderly: an analysis of surveillance, epidemiology and end results. Am J Obstet Gynecol 1986;154:639-647.
30. Garg PP, Kerlikowske K, Subak L, Grady D: Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-479.
31. Coughlin SS, Giustozzi A, Smith SJ, Lee NC: A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-375.
32. Negri E, Tzonou A, Beral V, Lagiou P, Trichopoulos D, Parazzini F, Franceschi S, Booth M, La Vecchia C: Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 1999;80:848-851.
33. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465.
34. Eeles RA, Tan S, Witshaw E, Fryatt I, a'Hem RP, Shepherd JH, Harmer CL, Blake PR, Chilves CE: Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259-262.
35. Ursic-Vrscaj M, Bebar S, Zakelj MP: Hormone replacement therapy after invasive ovarian serous cystoadenocarcinoma treatment: the effect on survival. Menopause 2001;8:70-75.
36. Guidozzi F, Daponte A: Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 1999;86:1013-1018.
37. Schindler AE: Hormone replacement therapy in women after genital cancer. Maturitas (suppl 1) 2002;41:105-111.
38. Biglia N, Gadducci A, Ponzone R, Roagna R, Sismondi P: Hormone replacement therapy in cancer survivors. Maturitas 2004;48:333-346.
39. Burger CW, van Leeuwen FE, Scheele F, Kenemans P: Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999;32:69-76.
40. Persson I, Yuen J, Bergkvist L, Schairer C: Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-332.
41. Ploch E: Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169-177.
42. El-Ghobashy AA, Shaaban AM, Herod J, Herrington CS: The pathology and management of endocervical glandular neoplasia. Int J Gynecol Cancer 2005;15:583-592.
43. Lacey JV, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael DC, McGowan L, Mortel R, Schwartz PE, Kurman RJ, Hildesheim A: Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000;77:149-154.
44. Sherman KJ, Daling JR, McKnight B, Chu J: Hormonal factors in vulvar cancer: a case-control study. J Reprod Med 1994;39:857-861.
45. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C: Risks of breast and endometrial cancer after estrogen and progestin replacement. Cancer Causes Control 1999;10:253-260.